1,4-二氮杂螺[4.5]-2-癸酮 | 19718-88-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1,4-二氮杂螺[4.5]-2-癸酮
• 英文名称: 1,4-diazaspiro[4.5]decan-2-one
• 英文别名: 1,4-diazaspiro[4.5]decan-3-one
• CAS: 19718-88-8
• 化学式: C₈H₁₄N₂O
• 分子量: 154.212
• InChiKey: FLZYHGIIDJMSJQ-UHFFFAOYSA-N

物化性质

• 熔点：
  121 °C
• 沸点：
  360.1±35.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  1,4-二氮杂螺[4.5]-2-癸酮 在 氢氧化钾 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 26.0h， 生成 4-Oxido-2-phenylmethoxy-1-aza-4-azoniaspiro[4.5]deca-1,3-diene
  参考文献：
  名称：

  Versatile Spirocyclic Glycine‐Based Nitrones and Their Highly Stereoselective 1,3‐Dipolar Cycloaddition

  摘要：

  A convenient and efficient method for the synthesis of novel spirocyclic nitrones prepared from glycine derivatives is reported. The 1,3-cycloaddition reactions of the nitrones with alkenes lead to novel isoxazolidines in high yields and with excellent regio- and stereoselectivity.

  DOI：

  10.1080/00397910601033781
• 作为产物：
  描述：

  环己酮 、 氨基乙腈 在 sodium methylate 作用下， 生成 1,4-二氮杂螺[4.5]-2-癸酮
  参考文献：
  名称：

  768.α-氨基腈与醛和酮的相互作用

  摘要：

  DOI：

  10.1039/jr9510003479

文献信息

• “Dry” and “Wet” Green Synthesis of 2,2′-Disubstituted Quinazolinones
  作者：Ferenc Miklós、Ferenc Fülöp

  DOI：10.1002/ejoc.200901052

  日期：2010.2

  (3), has been utilized to convert α- and β-aminocarboxamides 5a, 5b, 6a-c and 9 and cycloalkanones 2-2b and alkanones 2c-e into 1,4-diazaspiro-[4.5]decan-2-one (10) and cis-, diexo- or diendo-2,2'-disubstituted quinazolinones 5a, 5b, 7a-f and 8. diexo-Methylene-bridged carboxamides 6a and 6b were treated "on water" with N-benzylpiperidinone (11) to afford spiropiperidine-quinazolinones 12a and 12b. All

  在水性或无溶剂条件下非常方便、环境友好的螺环化反应，开发用于制备螺[环己烷-1,2'-(1'H)-喹唑啉]-4'(3'H)-one (3 )，已被用于将 α- 和 β-氨基甲酰胺 5a、5b、6a-c 和 9 以及环烷酮 2-2b 和烷酮 2c-e 转化为 1,4-二氮杂螺-[4.5]癸烷-2-one (10)和顺-、二外-或二烯-2,2'-二取代的喹唑啉酮5a、5b、7a-f和8。用N-苄基哌啶酮(11)“在水上”处理二外-亚甲基桥连的羧酰胺6a和6b，得到螺哌啶-喹唑啉酮 12a 和 12b。所有这些反应均在室温下进行，没有任何催化剂或助溶剂，产率高达 99%。
• Novel rearrangement of substituted spiroimidazolidinones into quinoline derivatives via Vilsmeier-Haack reagent
  作者：Oleg К. Farat、Nikolai V. Smetanin、Svetlana A. Varenichenko、Mariia B. Kaidash、Ekaterina V. Zaliznaya、Victor I. Markov

  DOI：10.1016/j.tetlet.2021.153464

  日期：2021.11

  A novel rearrangement was discovered by reacting 1,4-diazaspiro-[4,5]-decan-2-ones with a Vilsmeier-Haack reagent to give previously unknown aminoquinoline derivatives. The reaction proceeds as an electrophilic rearrangement under mild conditions with a satisfactory yield of reaction products.

  通过将 1,4-二氮杂螺-[4,5]-癸烷-2-ones 与 Vilsmeier-Haack 试剂反应生成以前未知的氨基喹啉衍生物，发现了一种新的重排。该反应在温和条件下以亲电重排的形式进行，反应产物的产率令人满意。
• MNK INHIBITORS AND METHODS RELATED THERETO
  申请人：eFFECTOR Therapeutics, Inc.

  公开号：US20180085368A1

  公开（公告）日：2018-03-29

  The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4a , R 4b , R 5 , R 6 , R 7 , R 8 , W 1 , W 2 , Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.

  本发明涉及式（I）化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中R1、R2、R3、R4a、R4b、R5、R6、R7、R8、W1、W2、Y和n如本文所定义。还描述了式I化合物的药学上可接受的组成物，以及利用式I化合物和药学上可接受的式I化合物组成物作为Mnk抑制剂以及治疗癌症等疾病的治疗剂的方法。
• Process for the preparation of pyrrolidone derivatives
  申请人：I.S.F. Societa Per Azioni

  公开号：US04797496A1

  公开（公告）日：1989-01-10

  Process for preparing pyrrolidinone derivatives of (1) ##STR1## in which R is hydrogen, alkyl or acyl characterized in that a compound of (2) ##STR2## wherein R.sup.1 is hydrogen and R.sup.2 is benzyl or substituted benzyl, or R.sup.1 and R.sup.2 can together form a group ##STR3## where R.sup.4 and R.sup.5 are independently hydrogen, alkyl, phenyl or optionally substituted aryl or together are 1,4-butylene or 1,5-pentylene; R.sup.3 is hydrogen or straight or branched alkyl of 1 to 4 carbon atoms; and X is alkyl subjected to N-deprotection and the deprotected intermediate is cyclized intramolecularly. The deprotected intermediates can be isolated as acid-addition salts.

  制备(1)中的吡咯烷酮衍生物的过程，其中R为氢，烷基或酰基，其特征在于将化合物(2) ##STR2##其中R.sup.1为氢，R.sup.2为苄基或取代苄基，或R.sup.1和R.sup.2可以共同形成一个基团##STR3##其中R.sup.4和R.sup.5独立地为氢，烷基，苯基或可选取代芳基，或者共同为1,4-丁二烯或1,5-戊二烯;R.sup.3为氢或1至4个碳原子的直链或支链烷基;X为经N去保护的烷基，并且去保护的中间体通过分子内环化。去保护的中间体可以作为酸加合盐进行分离。
• Chemical compounds
  申请人：ISF SOCIETA PER AZIONI

  公开号：EP0207680A2

  公开（公告）日：1987-01-07

  Compounds of Structure (1): in which R' is H, C1-5 alkyl (straight or branched), or phenyl; W is a bond, -NHC.HR6CO- or -NHCHR6CONH-CHR7CO-, where R6 and R7, which can be the same or different are H or C1-6 alkyl (straight or branched); R2 is H, C1-5 alkyl (straight or branched), aryl or a benzyl group optionally substituted by C1-5 alkyl (straight or branched), C1-4, alkoxy (straight or branched) or hydroxy; R3 and R4, which can be the same or different, are H, C1-5 alkyl (straight or branched) or phenyl, or R3 and R4 can together form a 1,4-butylene or 1,5-pentylene group; R6 is H or -CHR8CONR9R10, where R8, R9 and R'°, which can be the same or different, are H or C1-5 alkyl (straight or branched); R" and R12, which can be the same or different, are H, C1-5 alkyl (straight or branched), or acyl or together with the nitrogen atom shown form a 2-oxo-pyrrolidino group optionally substituted in the 4-position by a hydroxy or C1-5 (straight or branched) alkoxy group, or a 5-oxo-1-imidazolidine group optionally substituted at the 2- position by one or two C1-5 alkyl groups or a 1,4-butylene or 1,5-pentylene group, or optionally substituted at the 4-position by C1-5 alkyl, or a pharmaceutically acceptable salt thereof, processes and intermediates for making them, pharmaceutical compositions containing them and their use as nootropic agents.

  结构 (1) 的化合物： 其中 R' 是 H、C1-5 烷基（直链或支链）或苯基； W 是键、-NHC.HR6CO- 或 -NHCHR6CONH-CHR7CO-，其中 R6 和 R7（可以相同或不同）是 H 或 C1-6 烷基（直链或支链）； R2 是 H、C1-5 烷基（直链或支链）、芳基或任选被 C1-5 烷基（直链或支链）、C1-4、烷氧基（直链或支链）或羟基取代的苄基； R3 和 R4（可以相同或不同）是 H、C1-5 烷基（直链或支链）或苯基，或 R3 和 R4 可共同形成 1，4-丁烯或 1，5-戊烯基团； R6 是 H 或 -CHR8CONR9R10，其中 R8、R9 和 R'° 可以相同或不同，是 H 或 C1-5 烷基（直链或支链）； R "和 R12（可以相同或不同）是 H、C1-5 烷基（直链或支链）或酰基，或与所示的氮原子一起形成 2-氧代吡咯烷基，可选择在 4 位被羟基或 C1-5（直链或支链）烷氧基取代、或 5-氧代-1-咪唑烷基，可选择在 2-位被一个或两个 C1-5 烷基或 1,4-丁烯或 1,5-戊烯基取代，或可选择在 4-位被 C1-5 烷基取代，或其药学上可接受的盐、制造它们的工艺和中间体、含有它们的药物组合物，以及它们作为促智剂的用途。